183 related articles for article (PubMed ID: 31525693)
1. The first integrins β3-mediated cellular and nuclear targeting therapeutics for prostate cancer.
Zhang L; Shan X; Meng X; Gu T; Lu Q; Zhang J; Chen J; Jiang Q; Ning X
Biomaterials; 2019 Dec; 223():119471. PubMed ID: 31525693
[TBL] [Abstract][Full Text] [Related]
2. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
[TBL] [Abstract][Full Text] [Related]
3. The ligand recognition specificity of beta3 integrins.
Suehiro K; Smith JW; Plow EF
J Biol Chem; 1996 Apr; 271(17):10365-71. PubMed ID: 8626608
[TBL] [Abstract][Full Text] [Related]
4. Beta3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells.
Wang X; Ferreira AM; Shao Q; Laird DW; Sandig M
Prostate; 2005 Apr; 63(1):65-80. PubMed ID: 15468167
[TBL] [Abstract][Full Text] [Related]
5. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
6. Screening a DNA Aptamer Specifically Targeting Integrin β3 and Partially Inhibiting Tumor Cell Migration.
Teng X; Wang Y; You L; Wei L; Zhang C; Du Y
Anal Chem; 2023 Aug; 95(33):12406-12418. PubMed ID: 37555842
[TBL] [Abstract][Full Text] [Related]
7. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
8. Bifunctional ligands that target cells displaying the alpha v beta3 integrin.
Owen RM; Carlson CB; Xu J; Mowery P; Fasella E; Kiessling LL
Chembiochem; 2007 Jan; 8(1):68-82. PubMed ID: 17154219
[TBL] [Abstract][Full Text] [Related]
9. Smart pH-Sensitive Nanogels for Enhancing Synergistic Anticancer Effects of Integrin α
Xu Y; Sun L; Feng S; Chen J; Gao Y; Guo L; An X; Nie Y; Zhang Y; Liu X; Ning X
ACS Appl Mater Interfaces; 2019 Sep; 11(38):34663-34675. PubMed ID: 31490654
[TBL] [Abstract][Full Text] [Related]
10. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
Demirgöz D; Garg A; Kokkoli E
Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
[TBL] [Abstract][Full Text] [Related]
11. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
12. Cell-permeable NF-κB inhibitor-conjugated liposomes for treatment of glioma.
Zhang Y; Zhang L; Hu Y; Jiang K; Li Z; Lin YZ; Wei G; Lu W
J Control Release; 2018 Nov; 289():102-113. PubMed ID: 30243823
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
Haubner R; Wester HJ; Reuning U; Senekowitsch-Schmidtke R; Diefenbach B; Kessler H; Stöcklin G; Schwaiger M
J Nucl Med; 1999 Jun; 40(6):1061-71. PubMed ID: 10452325
[TBL] [Abstract][Full Text] [Related]
14. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
15. PET imaging with [⁶⁸Ga]NOTA-RGD for prostate cancer: a comparative study with [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluoroethylcholine.
Israel I; Richter D; Stritzker J; van Ooschot M; Donat U; Buck AK; Samnick S
Curr Cancer Drug Targets; 2014; 14(4):371-9. PubMed ID: 24720338
[TBL] [Abstract][Full Text] [Related]
16. siRNA-mediated silencing of integrin β3 expression inhibits the metastatic potential of B16 melanoma cells.
Nasulewicz-Goldeman A; Uszczyńska B; Szczaurska-Nowak K; Wietrzyk J
Oncol Rep; 2012 Nov; 28(5):1567-73. PubMed ID: 22895695
[TBL] [Abstract][Full Text] [Related]
17. The role of protein disulfide isomerase in the post-ligation phase of β3 integrin-dependent cell adhesion.
Leader A; Mor-Cohen R; Ram R; Sheptovitsky V; Seligsohn U; Rosenberg N; Lahav J
Thromb Res; 2015 Dec; 136(6):1259-65. PubMed ID: 26514956
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases.
Fox GC; Su X; Davis JL; Xu Y; Kwakwa KA; Ross MH; Fontana F; Xiang J; Esser AK; Cordell E; Pagliai K; Dang HX; Sivapackiam J; Stewart SA; Maher CA; Bakewell SJ; Fitzpatrick JAJ; Sharma V; Achilefu S; Veis DJ; Lanza GM; Weilbaecher KN
Mol Cancer Ther; 2021 Jun; 20(6):1183-1198. PubMed ID: 33785647
[TBL] [Abstract][Full Text] [Related]
19. EDB-FN Targeted Peptide-Drug Conjugates for Use against Prostate Cancer.
Park SE; Shamloo K; Kristedja TA; Darwish S; Bisoffi M; Parang K; Tiwari RK
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31277465
[TBL] [Abstract][Full Text] [Related]
20. αvβ3 integrins negatively regulate cellular forces by phosphorylation of its distal NPXY site.
Milloud R; Destaing O; de Mets R; Bourrin-Reynard I; Oddou C; Delon A; Wang I; Albigès-Rizo C; Balland M
Biol Cell; 2017 Mar; 109(3):127-137. PubMed ID: 27990663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
